DESIGN AND ANTICANCER ACTIVITY PREDICTION OF DIHYROPYRIMIDINONE BASED NOVEL INHIBITORS OF P53-MDM2 INTERACTION
DOI:
https://doi.org/10.22159/ajpcr.2017.v10s4.21346Keywords:
Anticancer, Dihydropyrimidinone, MDM2, p53, ToxicityAbstract
Â
 Objective: P53 protein is well known for its role in cell cycle regulation and induction of apoptosis. This protein is degraded by MDM2 mediated proteolysis. Inhibition of interaction between p53 and MDM2 has been recognized as a most potential and selective target for development of novel anticancer agents. Recently, several molecules entered in the clinical trial study for the treatment of various types of cancers are based on inhibition of interaction between p53-MDM2. Therefore, in this study, a novel dihydropyridine based molecules were designed as p53-MDM2 inhibitor, and their anticancer activity (including reference) was determined in comparison with most active anticancer agent and inactive anticancer agents in National Cancer Institute database using Cancer IN†server.
Methods: In this work, a novel dihydropyrimidinone based lead (L11) on the basis of molecular docking study, predicted IC50, anticancer activity, and toxicity profile were designed. Lead L11 was obtained after sequential isosteric replacement of functional groups for optimization in compound L0.
Results: The docking scores of L3-L11 found to be in range of 21-25 close to docking score 25 of SAR405838 and better than nutlin-3a. MDM2 binding affinity values (37-78 Kcal/mol) of all ligands were also found to better than that of nutlin-3a (37 Kcal/mol). Surprisingly, MDM2 binding affinity of L11 (78 Kcal/mol) found to be equal to that of SAR405838 and 2-fold greater than nutlin-3a.
Conclusion: These data indicating that L11 as a potential lead from dihydropyrimidinones for inhibition of p53-MDM2 interaction.
Downloads
References
Nayak SK, Panesar PS, Kumar H. Non-genotoxic p53-activators and their significance as antitumor therapy of future. Curr Med Chem 2011;18(7):1038-49.
Böttger A, Böttger V, Garcia-Echeverria C, Chène P, Hochkeppel HK, Sampson W, et al. Molecular characterization of the hdm2-p53 interaction. J Mol Biol 1997;269(5):744-56.
Secchiero P, di Iasio MG, Gonelli A, Zauli G. The MDM2 inhibitor nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des 2008;14(21):2100-10.
Zhao Y, Yu S, Sun W, Liu L, Lu J, McEachern D, et al. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J Med Chem 2013;56(13):5553-61.
Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, et al. Discovery of a dihydroisoquinolinone derivative (NVP-CGM097): A highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors. J Med Chem 2015;58(16):6348-58. 6. Soares J, Espadinha M, Raimundo L, Ramos H, Gomes AS, Gomes S, et al. DIMP53-1: A novel small-molecule dual inhibitor of p53- MDM2/X interactions with multifunctional p53-dependent anticancer properties. Mol Oncol 2017;11(6):612-27.
Puri S, Kaur B, Parmar A, Kumar H. Ultrasound promoted Cu(Clo4)2 catalyzed rapid synthesis of substituted1, 2, 3, 4-tetrahydropyrimidine- 2-ones & hantzsch 1, 4-dihydropyridines in dry media. Heterocycl Comm 2009;15(1):51-5.
Kaur M. Study of Perchlorates as Catalysts for Construction of Organic Molecular Frameworks. Master’s Dissertation, Lovely Professional University; 2014.
Singh H, Kumar R, Singh S, Chaudhary K, Gautam A, Raghava GP. Prediction of anticancer molecules using hybrid model developed on molecules screened against NCI-60 cancer cell lines. BMC Cancer 2016;16:77.
Li GH, Huang JF. CDRUG: A web server for predicting anticancer activity of chemical compounds. Bioinformatics 2012;28(24):3334-5.
Kumar R, Chaudhary K, Singla D, Gautam A, Raghava GP. Designing of promiscuous inhibitors against pancreatic cancer cell lines. Sci Rep 2014;4:4668.
Drwal MN, Banerjee P, Dunkel M, Wettig MR, Preissner R. ProTox: A web server for the in silico prediction of rodent oral toxicity. Nucleic Acids Res 2014;42:W53-8.
Zaretzki J, Bergeron C, Rydberg P, Huang TW, Bennett KP, Breneman CM. RS-predictor: A new tool for predicting sites of cytochrome P450-mediated metabolism applied to CYP 3A4. J Chem Inf Model 2011;51(7):1667-89.
Available from: http://www.www-metaprint2d.ch.cam.ac.uk/ metaprint2d. [Last cited on 2017 Mar 27].
Available from: http://www.www-metaprint2d.ch.cam.ac.uk/ metaprint2d-react. [Last cited on 2017 Mar 27].
Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, Lim E. Clinical overview of MDM2/X-targeted therapies. Front Oncol 2016;6:7.
Wang S, Zhao Y, Bernard D, Aguilar A, Kumar S. Targeting the MDM2-p53 protein-protein interaction for new cancer therapeutics. Top Med Chem 2012;8:57-80.
Wang S, Sun W, Zhao Y, McEachern D, Meaux I, Barrière C, et al. SAR405838: An optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res 2014;74(20):5855-65.
Liu SX, Geng YZ, Yan SW. Structural effects and competition mechanisms targeting the interactions between p53 and MDM2 for cancer therapy. Front Phys 2017;12:128908.
Ribeiro CJ, Rodrigues CM, Moreira R, Santos MM. Chemical variations on the p53 reactivation theme. Pharmaceuticals (Basel) 2016;9(2). pii:E25.
Danelius E, Pettersson M, Bred M, Min J, Waddell MB, Guy RK, et al. Flexibility is important for inhibition of the MDM2/p53 protein-protein interaction by cyclic ß-hairpins. Org Biomol Chem 2016;14(44):10386-93.
Butina D. Unsupervised data base clustering based on daylight’s fingerprint and animator similarity: A fast and automated way to cluster small and large data sets. J Chem Inf Comput Sci 1999;39(4):747-50.
Wang W, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, et al. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice. Gastroenterology 2014;147(4):893-902.e2.
Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J, et al. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer 2010;46(6):1122-31.
Puszynski K, Gandolfi A, d’Onofrio A. The pharmacodynamics of the p53-Mdm2 targeting drug nutlin: The role of gene-switching noise. PLoS Comput Biol 2014;10(12):e1003991.
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138(1):103-41.
Tan CY, Saw TY, Fong CW, Ho HK. Comparative hepatoprotective effects of tocotrienol analogs against drug-induced liver injury. Redox Biol 2015;4:308-20.
Lamb DC, Waterman MR, Kelly SL, Guengerich FP. Cytochromes P450 and drug discovery. Curr Opin Biotechnol 2007;18(6):504-12.
Zhang F, Tagen M, Throm S, Mallari J, Miller L, Guy RK, et al. Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos 2011;39(1):15-21.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
